相关实验视频
Updated: Jan 12, 2026
09:44
Neuro-rehabilitation Approach for Sudden Sensorineural Hearing Loss
Published on: January 25, 2016
19.7K
低老年人营养风险指数预测老年人不良结果 突发感官神经听力损失患者
Shu-Yu Tai1,2, Leong-Perng Chan3,4, Chin-Kuo Chen5,6
1Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
概括
老年营养风险指数 (GNRI) 可以预测突然神经感官听力损失 (SSNHL) 的老年人听力恢复. 低GNRI,头和严重的初始听力损失与SSNHL患者的不良结果有关.
科学领域:
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
- 老年病的医生 老年病的医生
- 营养科学 营养科学
背景情况:
- 突然感觉神经听力损失 (SSNHL) 是一种影响老年人的严重疾病.
- 营养不良对老年人SSNHL恢复的影响尚不清楚.
- 代谢综合征,肥胖和白蛋白水平是与SSNHL相关的已知因素.
研究的目的:
- 调查老年营养风险指数 (GNRI) 与SSNHL老年患者 (65岁以上) 的临床结果之间的关联.
- 确定GNRI是否可以作为这个人口群体听力恢复的预测工具.
主要方法:
- 进行了一项观察性回顾性研究,对328名65岁以上被诊断为SSNHL的患者进行了观察.
- 使用体重,身高和血清白蛋白水平计算GNRI.
- 听力恢复根据听力测量改善被归类为有利或不利;所有患者都接受了类固醇治疗.
主要成果:
- 32.62%的患者经历了有利的听力恢复,而67.38%的患者有不利的结果.
- 低GNRI (<99) 与不良的临床结果显著相关 (OR=1.91,P=.0151).
- 多变量分析确定了头 (aOR=3.45),更严重的初始听力损失 (单位风险增加2%;P=.0015) 和低GNRI (aOR=1.79) 作为不良恢复的预测因素.
结论:
- 通过GNRI评估的营养状况对于预测老年SSNHL患者的临床结果至关重要.
- GNRI是一种简单且易于使用的标志物,用于识别患有听力恢复不良风险较高的老年SSNHL患者.
- 头,严重的初始听力损失和低GNRI是老年SSNHL患者服用类固醇治疗不良结果的指标.
相关概念视频
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
226
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
226
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
221
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
221
01:15Drug Dosing: Geriatric Patients
215
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
215
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
213
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
213
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
188
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
188